Stockreport

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

DBV Technologies S.A. - American Depositary Shares  (DBVT) 
US:NASDAQ Investor Relations: dbv-technologies.com/en/investor-relations
PDF Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Childre [Read more]